Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1985 1
1986 3
1989 1
1990 5
1991 3
1992 3
1993 4
1994 9
1995 8
1996 8
1997 10
1998 10
1999 14
2000 11
2001 11
2002 25
2003 22
2004 21
2005 17
2006 23
2007 24
2008 30
2009 30
2010 46
2011 47
2012 57
2013 41
2014 61
2015 73
2016 90
2017 93
2018 76
2019 61
2020 59
2021 67
2022 56
2023 68
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

1,058 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Very High Risk Myelodysplastic Syndrome"
Page 1
New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A, Bravo GM. Bazinet A, et al. Curr Treat Options Oncol. 2022 May;23(5):668-687. doi: 10.1007/s11864-022-00965-1. Epub 2022 Mar 23. Curr Treat Options Oncol. 2022. PMID: 35320468 Review.
The treatment of myelodysplastic syndromes (MDS) begins with risk stratification using a validated tool such as the International Prognostic Scoring System (IPSS) or its revised version (IPSS-R). ...In addition, careful individualized risk stratificati …
The treatment of myelodysplastic syndromes (MDS) begins with risk stratification using a validated tool such as the Int …
NCCN Guidelines Insights: Myelodysplastic Syndromes, Version 3.2022.
Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. Greenberg PL, et al. J Natl Compr Canc Netw. 2022 Feb;20(2):106-117. doi: 10.6004/jnccn.2022.0009. J Natl Compr Canc Netw. 2022. PMID: 35130502
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information o …
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management …
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Kadia TM, et al. Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7. Lancet Haematol. 2021. PMID: 34329576 Free PMC article. Clinical Trial.
Here we report on the independent cohort investigating the safety and activity of venetoclax added to intensive chemotherapy (the CLIA regimen [cladribine, high-dose cytarabine, idarubicin]). Eligible patients were aged 18-65 years with a new diagnosis of acute myeloid leu …
Here we report on the independent cohort investigating the safety and activity of venetoclax added to intensive chemotherapy (the CLIA regim …
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, Biemond BJ, Breems DA, Maertens J, van Marwijk Kooy M, Pabst T, de Weerdt O, Ossenkoppele GJ, van de Loosdrecht AA, Huls GA, Cornelissen JJ, Beverloo HB, Löwenberg B, Jongen-Lavrencic M, Valk PJM. Grob T, et al. Blood. 2022 Apr 14;139(15):2347-2354. doi: 10.1182/blood.2021014472. Blood. 2022. PMID: 35108372 Free PMC article.
Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. ...
Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (M …
Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment.
Nachtkamp K, Kobbe G, Gattermann N, Germing U. Nachtkamp K, et al. Dtsch Arztebl Int. 2023 Mar 24;120(12):203-210. doi: 10.3238/arztebl.m2023.0005. Dtsch Arztebl Int. 2023. PMID: 36718105 Free PMC article. Review.
BACKGROUND: Myelodysplastic syndromes (MDS) are malignant diseases arising from hematopoietic stem cells. Their overall incidence is 4 cases per 100 000 persons per year, and they are usually diagnosed when evaluating cytopenia. The median survival time is three yea …
BACKGROUND: Myelodysplastic syndromes (MDS) are malignant diseases arising from hematopoietic stem cells. Their overall incide …
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao LP, Caballero Berrocal JC, Sala C, Maggioni G, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, D'Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Mannina D, Lanino L, Chiusolo P, Giaccone L, Voso MT, Riva M, Oliva EN, Zampini M, Riva E, Nibourel O, Bicchieri M, Bolli N, Rambaldi A, Passamonti F, Savevski V, Santoro A, Germing U, Kordasti S, Santini V, Diez-Campelo M, Sanz G, Sole F, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta MG. Sauta E, et al. J Clin Oncol. 2023 May 20;41(15):2827-2842. doi: 10.1200/JCO.22.01784. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930857 Free PMC article.
PURPOSE: Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. ...In high-risk patients treated with hypomethylating agents (HMA), IPSS-M failed to stratify individual probabili …
PURPOSE: Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy …
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Kohlmann A, Miyano S, Haferlach C, Kern W, Ogawa S. Haferlach T, et al. Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220272 Free PMC article.
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). ...The status of 14 genes combined with conventional factors revealed a novel prognostic model ('Model-1') separating p …
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic …
Myelodysplastic syndrome.
Hofmann WK, Koeffler HP. Hofmann WK, et al. Annu Rev Med. 2005;56:1-16. doi: 10.1146/annurev.med.56.082103.104704. Annu Rev Med. 2005. PMID: 15660498 Review.
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute my …
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic sy …
Prognostic Markers of Myelodysplastic Syndromes.
Veryaskina YA, Titov SE, Kovynev IB, Pospelova TI, Zhimulev IF. Veryaskina YA, et al. Medicina (Kaunas). 2020 Jul 27;56(8):376. doi: 10.3390/medicina56080376. Medicina (Kaunas). 2020. PMID: 32727068 Free PMC article. Review.
Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage dysplasia, peripheral blood cytopenias, and a high risk of transformation to acute myeloid leukemia. ...
Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage dysplasia, peripheral blood cytopenias, and a …
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Bose P, et al. Clin Infect Dis. 2021 May 18;72(10):1755-1763. doi: 10.1093/cid/ciaa358. Clin Infect Dis. 2021. PMID: 32236406 Free PMC article. Clinical Trial.
BACKGROUND: Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC …
BACKGROUND: Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute mye …
1,058 results